Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib for Steroid-refractory GVHD
NCT02997280Phase 2Completed
- Sponsor
- First Saint Petersburg State Medical University
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in graft-versus-host disease (GVHD), sponsored by First Saint Petersburg State Medical University. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT02997280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02997280.